Erratum: Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia (Proceedings of the National Academy of Sciences of the United States of America (2013) 110 (18644-18649) DOI: 10.1073/pnas.1318257110);Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 46, 2013, Pages 18644-18649

  Tamma, Roberto ^a   Sun, Li ^b   Cuscito, Concetta ^a   Lu, Ping ^b   Corcelli, Michelangelo ^a   Li, Jianhua ^b   Colaianni, Graziana ^a   Moonga, Surinder S ^b   Di Benedetto, Adriana ^a   Grano, Maria ^a   Colucci, Silvia ^a   Yuen, Tony ^b   New, Maria I ^b   Zallone, Alberta ^a   Zaidi, Mone ^b  

^a UNIVERSITY OF BARI   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Osteopenia; Oxytocin; Pituitary hormone

Indexed keywords

ARGININE VASOPRESSIN RECEPTOR 1 ALPHA; ARGININE VASOPRESSIN RECEPTOR 2 ALPHA; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE DEVELOPMENT; BONE MASS; BONE REMODELING; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; HYPONATREMIA; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOBLASTOGENESIS; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

MUS;

EID: 84887440981     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1415306111     Document Type: Erratum

References (32)

1. Abe E, et al. (2003) TSH is a negative regulator of skeletal remodeling. Cell 115(2):151-162. (Pubitemid 37329579)
2. Sun L, et al. (2006) FSH directly regulates bone mass. Cell 125(2):247-260.
3. Zaidi M, et al. (2010) ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc Natl Acad Sci USA 107(19):8782-8787.
4. Tamma R, et al. (2009) Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci USA 106(17):7149-7154.
5. Zaidi M, et al. (2013) The pituitary-bone connection. Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 8th ed. eds Rosen CJ, Bouillon R, Compston JE, Rosen V (Wiley-Blackwell, Hoboken, NJ), pp 969-977.
6. Baliram R, et al. (2012) Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest 122(10):3737-3741.
7. Zhu LL, et al. (2012) Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci USA 109(36):14574-14579.
8. Liu X, et al. (2009) Oxytocin deficiency impairs maternal skeletal remodeling. Biochem Biophys Res Commun 388(1):161-166.
9. Hruby VJ, Chow MS, Smith DD (1990) Conformational and structural considerations in oxytocin-receptor binding and biological activity. Annu Rev Pharmacol Toxicol 30:501-534.
10. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119(1):e1-e8.
11. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA (2010) Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 5(2):275- 280.
12. Verbalis JG, et al. (2010) Hyponatremia-induced osteoporosis. J Bone Miner Res 25(3): 554-563.
13. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G (2008) Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 101(7):583-588. (Pubitemid 351912001)
14. Sandhu HS, Gilles E, DeVita MV, Panagopoulos G, Michelis MF (2009) Hyponatremia associated with large-bone fracture in elderly patients. Int Urol Nephrol 41(3):733-737.
15. Barsony J, Sugimura Y, Verbalis JG (2011) Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem 286(12): 10864-10875.
16. Hoorn EJ, et al. (2011) Mild hyponatremia as a risk factor for fractures: The Rotterdam Study. J Bone Miner Res 26(8):1822-1828.
17. Bergstrom WH, Wallace WM (1954) Bone as a sodium and potassium reservoir. J Clin Invest 33(6):867-873.
18. Bergstrom WH (1955) The participation of bone in total body sodium metabolism in the rat. J Clin Invest 34(7, Part 1):997-1004.
19. Sejling AS, Pedersen-Bjergaard U, Eiken P (2012) Syndrome of inappropriate ADH secretion and severe osteoporosis. J Clin Endocrinol Metab 97(12):4306-4310.
20. Miller M (2006) Hyponatremia and arginine vasopressin dysregulation: Mechanisms, clinical consequences, and management. J Am Geriatr Soc 54(2):345-353.
21. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13(7):791-801.
22. Colaianni G, et al. (2011) Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem Biophys Res Commun 411(3):512-515.
23. Colaianni G, et al. (2012) Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem 287(34):29159-29167.
24. Blair HC, et al. (2011) Skeletal receptors for steroid-family regulating glycoprotein hormones: A multilevel, integrated physiological control system. Ann NYAcad Sci 1240:26-31.
25. Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M (2013) Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 19(2):130-136.
26. Bale TL, Dorsa DM (1995) Regulation of oxytocin receptor messenger ribonucleic acid in the ventromedial hypothalamus by testosterone and its metabolites. Endocrinology 136(11):5135-5138.
27. Hasunuma I, et al. (2013) Roles of arginine vasotocin receptors in the brain and pituitary of submammalian vertebrates. Int Rev Cell Mol Biol 304:191-225.
28. Isales CM, Zaidi M, Blair HC (2010) ACTH is a novel regulator of bone mass. Ann N Y Acad Sci 1192:110-116.
29. Balla T, Nagy K, Tarján E, Renczes G, Spät A (1981) Effect of reduced extracellular sodium concentration on the function of adrenal zona glomerulosa: Studies in conscious rats. J Endocrinol 89(3):411-416. (Pubitemid 11127498)
30. Chhokar VS, et al. (2004) Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 287(5):H2023-H2026. (Pubitemid 39430739)
31. Carbone LD, et al. (2008) Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 52(2):135-138. (Pubitemid 351885442)
32. Hori M (2013) Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure. Future Cardiol 9(2):163-176.